Lowest Price Guaranteed
Pages
264
Last Updated
July 2026
View Count
18761
The global chronic kidney disease market size is valued at USD 38.91 billion in 2024 and is expected to reach USD 67.36 billion by 2035, representing a CAGR of 5.12% during the forecast period.
 |
To learn more about this report, request a free sample copy
Chronic kidney disease (CKD) refers to the long-term condition in which a patient gradually loses its kidney function. In most cases, patients suffering from chronic kidney disease remain undiagnosed until the kidney function declined to 75% as its symptoms are rarely observed (which include swollen ankles, foamy urine and blood in urine). A recent study of Centers for Disease Control and Prevention stated that, nearly 35.5 million people in the United States are suffering from chronic kidney condition and around 9 out of 10 adults with CKD are unaware of the disease. This growing incidence of disease resulted due to lack of awareness, limited epidemiological data and late diagnosis of the patients. In order to mitigate the increasing concern of chronic kidney conditions, several stakeholders in the pharmaceutical industry are actively exploring advanced therapeutic drugs and treatment that helps in managing disease condition. For instance, in March 2024, the USFDA approved Vafseo® (vadadusat) (developed by Akebia Therapeutics) for the treatment of anemia in adults with chronic kidney disease and receiving dialysis treatment.
It is worth mentioning that big pharmaceutical companies have also shown interest in this field. AstraZeneca has invested in the development of innovative disease model, namely 3D Kidney microphysiological systems. This innovative organ-on-chip model enables co-culturing of different types of cells, allowing cellular signaling and interaction to be investigated within diseased and healthy kidneys. It is worth noting here that AstraZeneca is also focused on using 3D bioprinting to prepare models of both kidney tubules and vessels, in order to understand the interplay in the real kidneys. It is important to highlight here that several start-ups have also taken initiatives to accelerate the development of targeted therapeutic solutions for chronic kidney disease management. In addition, industry players are also leveraging artificial intelligence (AI) and big data analytics for disease diagnosis at an early stage so as to provide appropriate and timely treatment to the patients. Driven by the increasing incidence and ongoing efforts of industry leaders, we believe the CKD market will continue to grow at a steady pace, offering opportunities for stakeholders to hold a strong foothold in the market for drug development.
The market report covers invaluable information about leading industry players who are currently active across various segments of the field as mentioned in the table below.
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Market Size 2035 | USD 67.36 billion | |
| Market CAGR (Till 2035) | 5.12% | |
| Type of Drug Class |
|
|
| Type of Molecule |
|
|
| Type of Treatment |
|
|
| Type of Disease Indication |
|
|
| Route of Administration |
|
|
| End User |
|
|
| Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |
One of the key objectives of chronic kidney disease market report was to estimate the current market size, opportunity and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period. Additionally, the market report features the likely distribution by type of drug class (ACE Inhibitors, Angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents, diuretics and other drug classes), type of molecule (small molecules and biologics), type of treatment (drugs, dialysis, transplantation of kidneys), disease indication (diabetic nephropathy, glomerulonephritis, hypertensive nephropathy, polycystic kidney disease and other indications), route of administration (oral and parenteral), end user (hospitals and clinics, ambulatory surgery centers, and dialysis centers), and geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa and Latin America).
To account for the uncertainties associated with the development of chronic kidney disease therapeutics and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.
Based on the type of drug class, the global chronic kidney disease market is segmented into ACE inhibitors, angiotensin-ii receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents, diuretics and other drug classes. According to our projection, ACE inhibitors hold the highest share (~25%) of the overall market. This can be attributed to the fact that ACE inhibitors serve as the first line of treatment to treat a wide range of chronic kidney diseases, such as hypertensive nephropathy and diabetic nephropathy. Furthermore, ACE inhibitors has shown significant potential in slowing disease progression by reducing proteinuria.
It is important to highlight here that patients with chronic kidney diseases loses the ability to produce erythropoietin that leads to the reduction in oxygen-carrying capacity. Thus, due to low production of erythropoietin, patients may suffer from anemia, which in turn surge the demand for erythropoietin stimulating agents. Erythropoietin stimulating agents (ESAs) play a crucial role in relieving anemia in patients by stimulating bone marrow for the production of red blood cells. Driven by the increasing usage in relieving anemia, ESAs will grow at a higher CAGR during the forecast period.
Other drug class includes cell therapies under development for CKD, with the aim to offer a treatment option for patients and prevent them from leading to dialysis. As stated by to Bruce Cullerton, CEO at ProKidney in a recent webinar “In the last 5 years we have seen more innovation in the kidney space than in the previous 20 years.” This company is developing a cell therapy REACT in phase II/III clinical trials.
Based on the type of molecule, the global CKD market is segmented into small molecules and biologics. According to our projection, small molecules segment accounts for the highest share of the overall market. This dominance is due to the fact that small molecules can easily reach the intracellular targets owing to their lower molecular weight, therefore, researchers are playing a significant role in the development of advanced therapies. However, the biologics segment will continue to grow at a higher CAGR during the forecast period. Biologics such as monoclonal antibodies offer high target specificity, selectivity, and stability, making them ideal for the development of therapeutic drugs to treat patients with CKD.
On the basis of treatment type, the global chronic kidney disease market size is segmented into drugs, dialysis and kidney transplant. Currently, chronic kidney disease drugs market segment occupies the majority of the share of overall market. This dominance is due to the growing government support for research and development of advanced drugs to treat patients with chronic kidney diseases. Furthermore, increasing focus on the identification of therapeutic treatment to slow down disease progression has further contributed to the growth of this segment. Additionally, several government organizations are taking strategic initiatives followed by funding and investment support to support the development of advanced therapeutic drugs. Driven by the ongoing government support, funding and research, the drug segment will continue to grow at a higher CAGR rate during the forecast period. There have been several private players that have taken initiatives to improve access to dialysis by increasing the density of dialysis centers available. One such company is India based VitusCare Medlife which began operations in July 2017 and has opened 35 dialysis centres in seven states.
Based on the disease indication, the global market is segmented into diabetic nephropathy, glomerulonephritis, hypertensive nephropathy, polycystic kidney disease and other indications. According to our projection, currently diabetic nephropathy accounts for the highest share of the market owing to the increasing incidence of diabetes epidemic. Furthermore, diabetic nephropathy is the common chronic kidney disease condition that can potentially damage kidney. Owing to the growing concern, several industrial leaders are emphasizing on the development of advanced drugs that can significantly slow the disease progression.
Based on the route of administration, the global market is segmented into oral and parenteral. According to our projection, presently the oral route accounts for the highest chronic kidney disease market share (close to 60%). This largest share is due to the convenience of administration for managing chronic kidney disease condition. Moreover, oral route of administration is preferred by the geriatric population. However, in the long run, parenteral administration is estimated to grow at a higher CAGR during the forecast period. This substantial growth rate is due to the increasing usage of targeted therapies that are delivered through intravenous / subcutaneous routes.
Based on end users, the global CKD market is segmented into hospitals and clinics, ambulatory surgery centers, and dialysis centers. According to our projection, hospitals occupy the highest share of the market. This dominance is due to the availability of healthcare experts, advanced technological devices and treatment facilities in hospitals. Moreover, patients with CKD require comprehensive treatment and disease management, which further contributed to the highest share of the market. It is important to highlight here that patients with late-stage chronic kidney disease require frequent dialysis, which is anticipated to create a burden on the healthcare sector. As a result, patients is likely to avail specialized treatment and dialysis services outside the hospital settings, which is anticipated to be a key reason for the highest CAGR of dialysis centers during the forecast period.
Based on the geographical region, the global market is distributed into North America, Europe, Asia-Pacific, Middle East and North Africa and Latin America. According to our analysis, currently North America accounts for the highest CKD market share of the overall market owing to the increasing prevalence of chronic kidney diseases in this region. Further, government and non-government organizations are making considerable investment in healthcare infrastructure to deliver optimal care to the patients with CKD in this region. However, the market in Asia-Pacific is anticipated to grow at a higher CAGR rate during the forecast period. This substantial growth is likely to be the result of increasing research on chronic kidney diseases, government initiatives to develop therapeutic drugs and to awareness among people. Additionally, the growing requirement for quality healthcare in Asian countries has boosted the chronic kidney disease market growth during the forecast period.
The “Chronic Kidney Disease Market: Global Forecast and Industry Trends, till 2035” market research report also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this market. The market report highlights the efforts of several stakeholders engaged in this market segment of various domains. Key takeaways of the market analysis are briefly discussed below.
Currently, the market landscape witnesses the presence of several industry and non-industry leaders who are accelerating their efforts for the development of innovative drugs. Some startups in this market include US based Klotho Therapeutics and ProKidney.
Driven by the increasing awareness about chronic kidney disease and adequate support from the government organizations, companies in the chronic kidney disease industry are leveraging strategic initiatives. In order to leverage the competitive edge, several stakeholders are entering into acquisition, collaboration and partnerships to increase their efforts for drug development and product enhancement. In August 2024, American Kidney Fund (AKF) announced the two players, Boehringer Ingelheim and Eli Lilly, have joined the AKF's Corporate Membership Program, wherein the companies will support in advancement of kidney disease research, treatment, awareness, prevention and early diagnosis. As more market leaders continue to make investments for research and development of chronic kidney disease treatment drug, we believe that market will grow at a steady rate during the forecast period.
The increasing incidence of chronic kidney disease in population due to unhealthy dietary habits, acute kidney injury and sedentary lifestyle is the key driver of the market. Furthermore, the growing prevalence of diseases, such as hypertension and diabetes portray as risk factors in developing chronic kidney diseases. As per National Kidney Foundation 33% of the US adults are at the risk of developing kidney diseases. In order to mitigate the growing concern of disease, several industry stakeholders are focusing on technological advancements for the development of diagnostic tools, and therapeutic drugs is likely to contribute towards the growth of the market. In addition to treatment modalities, researchers are also emphasizing the development of innovative screening techniques and biomarkers for early detection of disease, through identifying the glomerular filtration rate.
Some of the key challenges that may impede the growth of market includes limited awareness and complex regulatory guidelines for the approval of therapeutic drugs. The market is also impacted due to the requirement of high initial investment for the development of therapeutic drugs and disease diagnostic methods. Furthermore, the procedure cost for dialysis is also high, preventing access to some patients in developing countries. However, in countries like India a government program, Pradhan Mantri National Dialysis Programme (PMNDP), was rolled out in April 2016 to offer dialysis at no cost. For this initiative, the Indian government set up 1,530 centres across the country.
With respect to the drugs the treatment price can limit their uptake. Akebia launched Vafseo at a price tag of $1,278 for a 30-day supply, equivalent to $15,500 per annum. At the same time GSK’s Jesduvroq is priced at $700 for a 30-day supply. Late diagnosis of disease may also affect the effectiveness of therapeutic drugs and limit the opportunities for healthcare experts to improve the kidney function. Moreover, the existing therapeutic drugs have shown several side effects, which may create challenges in the adoption of drugs on a large scale.
Despite challenges, several factors that have contributed towards the growth of the market include growing focus on the development of precision medicine. It is important to highlight here that chronic kidney disease is a heterogenous condition with different underlying causes. Therefore, players are emphasizing on the need for precision medicine (including molecular diagnostics and genetic profiling) that has contributed to the development of tailored therapeutics. It is important to highlight here that industrial leaders are focusing on the development of smart wearable devices, remote monitoring devices and telemedicine platforms to encourage disease management at home. These innovative factors and technological advancements have contributed to the chronic kidney disease market growth during the upcoming years.
The global chronic kidney disease market size is currently valued at USD 38.91 billion and is expected to grow at a CAGR of 5.12% during the forecast period. This substantial growth is likely to be the result of the growing incidence of kidney diseases across the globe. Driven by the growing concern, the industry leaders are accelerating their efforts for the development of novel drugs. Notably, in a research study published by University Medical Center Groningen in October 2024, Ozempic (a GLP-1 drug for the treatment of diabetes and obesity) has demonstrated positive effects on the obese patients (having no diabetes) with chronic kidney damage. The drug has resulted in less protein concentration in urine, reduced kidney inflammation and low blood pressure. As stated by Hiddo L Heerspink (Clinical Pharmacologist of the University) “All signals are green to test this drug in a large study. I would like to find out whether it can lead to fewer dialyses or kidney transplants. And I would also very much like to investigate whether this drug also works positively in patients with kidney damage without obesity.”
Examples of key companies who are currently engaged in the market (which have also been profiled in this market report; the complete list of is available in the full report) include AbbVie, Amgen, Abbott, AstraZeneca, Akebia Therapeutics, Bristol-Myers Squibb, Fresenius Medical Care, FibroGen, GlaxoSmithKline, Johnson & Johnson, Kissei Pharmaceutical, Merck, Novartis, Otsuka Pharmaceutical, Pfizer, LA Roche, Sanofi, Siemens Healthcare and Teva Pharmaceutical Industries.
Several recent developments have taken place in the field of chronic kidney disease. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall chronic kidney disease market trends that have been outlined in our analysis.